{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:59:57Z","timestamp":1761789597808},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.2169\/internalmedicine.2327-18","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T22:03:10Z","timestamp":1562709790000},"page":"3107-3111","source":"Crossref","is-referenced-by-count":6,"title":["Elevated Plasma Renin Activity Caused by Accelerated-malignant Hypertension in a Patient with Aldosterone-producing Adenoma Complicated with Renal Insufficiency"],"prefix":"10.2169","volume":"58","author":[{"given":"Tatsuya","family":"Maruhashi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Amioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ikenaga","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Physiology and Medicine, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuki","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihito","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan"},{"name":"Division of Regeneration and Medicine, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66: 607-618, 2007."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr J 58: 711-721, 2011.","DOI":"10.1507\/endocrj.EJ11-0133"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37: 253-390, 2014.","DOI":"10.1038\/hr.2014.20"},{"key":"4","unstructured":"4. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101: 1889-1916, 2016."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Monticone S, Viola A, Tizzani D, et al. Primary aldosteronism: who should be screened? Horm Metab Res 44: 163-169, 2012.","DOI":"10.1055\/s-0031-1295409"},{"key":"6","unstructured":"6. Kawazoe N, Eto T, Abe I, et al. Pathophysiology in malignant hypertension: with special reference to the renin-angiotensin system. Clin Cardiol 10: 513-518, 1987."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Oelkers W, Diederich S, Bahr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J Clin Endocrinol Metab 85: 3266-3270, 2000.","DOI":"10.1210\/jcem.85.9.6819"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zarifis J, Lip GY, Leatherdale B, Beevers G. Malignant hypertension in association with primary aldosteronism. Blood Press 5: 250-254, 1996.","DOI":"10.3109\/08037059609079679"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Catena C, Colussi G, Nadalini E, et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol 2: 722-731, 2007.","DOI":"10.2215\/CJN.00050107"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 66: 1-9, 2004.","DOI":"10.1111\/j.1523-1755.2004.00701.x"},{"key":"11","unstructured":"11. Baglin A, Weiss Y, Safar M, Milliez P. Primary hyperaldosteronism with malignant hypertension. Nouv Presse Med 2: 295-297, 1973 (in French)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iyori S, Saruta T, Kondo K, Ozawa Y, Hata J. Renin and juxtaglomerular apparatus in a patient with primary aldosteronism complicated by chronic renal failure. South Med J 69: 951-952, 1976.","DOI":"10.1097\/00007611-197607000-00051"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Iwaoka T, Umeda T, Sato T, Katsuragi S, Takeuchi T. High plasma renin activities in primary aldosteronism with malignant hypertension. A case report. Jpn Heart J 21: 423-428, 1980.","DOI":"10.1536\/ihj.21.423"},{"key":"14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000185866","volume":"54","author":"M Ideishi","year":"1990","unstructured":"14. Ideishi M, Kishikawa K, Kinoshita A, et al. High-renin malignant hypertension secondary to an aldosterone-producing adenoma. Nephron 54: 259-263, 1990.","journal-title":"Nephron","ISSN":"http:\/\/id.crossref.org\/issn\/0028-2766","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Oka K, Hayashi K, Nakazato T, Suzawa T, Fujiwara K, Saruta T. Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration. Intern Med 36: 700-704, 1997.","DOI":"10.2169\/internalmedicine.36.700"},{"key":"16","unstructured":"16. Suzuki H, Asano K, Eiro M, et al. Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE inhibitor. QJM 95: 128-130, 2002."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Prejbisz A, Klisiewicz A, Januszewicz A, et al. 22-year-old patient with malignant hypertension associated with primary aldosteronism. J Hum Hypertens 27: 138-140, 2013.","DOI":"10.1038\/jhh.2012.26"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ito H, Sasaoka A, Takao T, et al. Aldosterone-producing adrenocortical adenoma complicated by chronic renal failure. Case report and review of the literature. Am J Nephrol 18: 541-546, 1998.","DOI":"10.1159\/000013403"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243-1248, 2005.","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"20","unstructured":"20. Reincke M, Fischer E, Gerum S, et al.  Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 60: 618-624, 2012."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Wu VC, Wang SM, Chang CH, et al. Long term outcome of Aldosteronism after target treatments. Sci Rep 6: 32103, 2016.","DOI":"10.1038\/srep32103"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_2327-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T03:42:17Z","timestamp":1572666137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_2327-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":21,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2327-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}